2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|August 15, 2016
Novartis Expands Biologics Production in France
Author(s)Pharmaceutical Technology Editors
Jacobs Engineering will provide engineering and construction services to expand the Novartis site in Huningue, France.
Advertisement
Jacobs Engineering Group was awarded a contract to expand the Novartis Pharma S.A.S. Biotechnology Center in Huningue, France, the company announced on Aug. 11, 2016. Under the terms of the agreement, Jacobs is providing engineering, procurement, and construction management services to increase the site’s production capacity by 70% and create a second line of purification that allows for multiple drugs to be manufactured simultaneously.
Already one of the world’s largest production facilities for monoclonal antibodies from mammalian cells, the expansion project adds cell culture bioreactors to the site. The $100 million expansion project is scheduled to be completed in four years. Jacobs’ services are being led from its operations in Milan, Italy.
Source:
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement